Search for: "PFIZER" Results 1241 - 1260 of 4,632
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
According to the Wall Street Journal, Pfizer Inc released a public statement on Saturday, January 6, 2018, announcing the end of R & D for new drugs for treatment of Alzheimer's Disease and Parkinson's Disease. [read post]
30 Dec 2017, 7:44 am
The combined company would have been called Pfizer and would have been led by Pfizer’s current CEO, Ian Read, but the deal was being structured so that, at least on paper, Allergan would have been the buyer. [read post]
29 Dec 2017, 10:05 am by Paul Caron
Bloomberg: 'Orwellian' Offshore Tax Will Hit Some Firms Harder Than Others, by Lynnley Browning: The name that Republican tax writers gave to a new, multi billion-dollar business levy implies that it targets foreign earnings from “intangible” intellectual property — hitting tech firms and drugmakers like Apple and Pfizer. [read post]
9 Dec 2017, 9:46 pm by Mark Summerfield
  The primary judge had determined that evidence provided by an expert witness on behalf of Pfizer did not provide a reasonable basis for its belief that SBA was infringing the Pfizer patents, but rather amounted to ‘mere suspicion’. [read post]
1 Dec 2017, 11:35 am by Nate Nead
Pfizer remains the top industry prescription sales leader.[3] Revenues and R&D of Top Pharma Companies[4] Key Factors Driving Demand The benefits of using oral therapies is influencing pharmaceutical companies to develop new and improved oral therapies to support patients who need accuracy of dose, convenience and ease of compliance to medication regimen. [read post]
22 Nov 2017, 8:17 am by Nate Nead
Within the last three years, we have seen pure play companies get acquired and large companies deepen or broaden their category presence, such as Procter & Gamble’s purchase of New Chapter, the Carlyle Group’s purchase of NBTY (Nature’s Bounty), and Pfizer’s purchase of Alacer. [read post]
20 Nov 2017, 6:21 am by Kluwer UPC News blogger
That treaty originated in initiatives in the early 1980s by Edmund Pratt, CEO of the American pharmaceuticals company Pfizer, and John Opel, CEO of the computer company IBM. [read post]
17 Nov 2017, 3:00 am by John Jenkins
., Pfizer Inc. and PayPal Holdings, Inc., according to filings and a spokesman for the money manager. [read post]
12 Nov 2017, 11:00 pm by Kevin LaCroix
A recurring issue in securities cases involves the question of when plaintiffs may rely on the presumption of reliance under the fraud on the market doctrine. [read post]
11 Nov 2017, 1:55 am
 A diverse speaking faculty includes representatives from The Broad Institute, Mylan, Novartis, Pfizer and Teva. [read post]
9 Nov 2017, 2:00 am by Shelby Hoffman
The zoning map and text amendments will convert the former Pfizer factory site, currently used for parking, […] The post Council Passes Contentious Pfizer Sites Rezoning in Williamsburg appeared first on CityLand. [read post]
1 Nov 2017, 7:39 am by Attorney Bert Louthian
In September 2017, the Food and Drug Administration wrote a letter to Pfizer, the maker of the EpiPen, stating that the company had failed to investigate claims of defective units.... [read post]
27 Oct 2017, 2:59 pm by Mike Mireles
The LA Times recently published an article, "UCLA’s Efforts to Patent a Costly Patent Cancer Drug in India Hurts the Poor, Critics Say,” concerning Pfizer’s drug, Xtandi. [read post]
19 Oct 2017, 6:08 am by Lindsay Offutt
The lawsuit, filed in the US District Court for the District of Columbia [official website], accuses defendants AstraZeneca, GE Healthcare, Johnson & Johnson, Pfizer and Roche of violating several provisions of the federal Anti-Terrorism Act... [read post]
11 Oct 2017, 9:42 am by Dennis Crouch
To date, twenty leading global research-based biopharmaceutical companies, including founders Novartis, GSK, Pfizer and Merck KGaA, have committed to participate, and we anticipate more. [read post]
11 Oct 2017, 8:17 am
RetroKatsDarren Meale (Simmons & Simmons and IPEC DDJ) returns with the second volume of his round up of trade mark litigation. [read post]